Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nemolizumab is a subcutaneously administered humanized monoclonal antibody against interleukin-31 receptor A, which is involved in pruritus and inflammation in atopic dermatitis. In phase 2 studies, nemolizumab lessened the severity of atopic dermatitis. METHODS: In a 16-week, double-blind, phase 3 trial, we randomly assigned Japanese patients with atopic dermatitis and moderate-to-severe pruritus and an inadequate response to topical agents in a 2:1 ratio to receive subcutaneous nemolizumab (60 mg) or placebo every 4 weeks until week 16, with concomitant topical agents. The primary end point was the mean percent change in the visual-analogue scale (VAS) score for pruritus (range, 0 to 100, with higher scores indicating worse pruritus) from baseline to week 16. Secondary end points included the time course of change in the VAS score for pruritus up to week 4, the change in the Eczema Area and Severity Index (EASI) score (range, 0 to 72, with higher scores indicating greater severity), a score of 4 or less on the Dermatology Life Quality Index (DLQI; range, 0 to 30, with higher scores indicating a greater effect on daily life), a score of 7 or less on the Insomnia Severity Index (ISI; range, 0 to 28, with higher scores indicating greater severity), and safety. RESULTS: A total of 143 patients were randomly assigned to receive nemolizumab and 72 to receive placebo. The median VAS score for pruritus at baseline was 75. At week 16, the mean percent change in the VAS score was -42.8% in the nemolizumab group and -21.4% in the placebo group (difference, -21.5 percentage points; 95% confidence interval, -30.2 to -12.7; P<0.001). The mean percent change in the EASI score was -45.9% with nemolizumab and -33.2% with placebo. The percentage of patients with a DLQI score of 4 or less was 40% in the nemolizumab group and 22% in the placebo group; the percentage of patients with an ISI score of 7 or less was 55% and 21%, respectively. The incidence of injection-related reactions was 8% with nemolizumab and 3% with placebo. CONCLUSIONS: In this 16-week trial, the use of subcutaneous nemolizumab in addition to topical agents for atopic dermatitis resulted in a greater reduction in pruritus than placebo plus topical agents. The incidence of injection-site reactions was greater with nemolizumab than with placebo. Longer and larger trials are necessary to determine whether nemolizumab has a durable effect and is safe for atopic dermatitis. (Funded by Maruho; JapicCTI number, 173740.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The EASI score showed a moderate improvement of 46% with nemolizumab versus 33% in the placebo group192.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [192]
In the citing paper
“The overall efficacy in pruritus in combination with TCSs was further confirmed in a phase III study over 16 weeks with a decrease of 43% versus 21% in the placebo group as measured by the visual analogue scale score.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [192]
Citations
Cites
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
Diagnostic features of atopic dermatitis
Hanifin, J. M., & Rajka, G. (1980) · Acta Dermato-Venereologica · doi:10.2340/00015555924447 · Cited by 5,086
Morin, C. M., Belleville, G., Bélanger, L., & Ivers, H. (2011) · Sleep · doi:10.1093/sleep/34.5.601 · Cited by 4,620
The Validity and Reproducibility of a Work Productivity and Activity Impairment Instrument
Reilly, M. C., Zbrozek, A. S., & Dukes, E. M. (1993) · PharmacoEconomics · doi:10.2165/00019053-199304050-00006 · Cited by 3,071
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Weidinger, S., Beck, L. A., Bieber, T., Kabashima, K., & Irvine, A. D. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0001-z · Cited by 1,549
Self-citationBlauvelt, A., de Bruin-Weller, M., Gooderham, M., Cather, J. C., Weisman, J., Pariser, D., Simpson, E. L., Papp, K. A., Hong, H. C.-H., Rubel, D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31191-1 · Cited by 1,261
Guidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Berger, T. G., Krol, A., Paller, A. S., Schwarzenberger, K., Bergman, J. N., Chamlin, S. L., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.023 · Cited by 1,224
Wollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14891 · Cited by 1,181
Guidelines of care for the management of atopic dermatitis
Sidbury, R., Davis, D. M., Cohen, D. E., Cordoro, K. M., Berger, T. G., Bergman, J. N., Chamlin, S. L., Cooper, K. D., Feldman, S. R., Hanifin, J. M., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.030 · Cited by 885
Research works printed but not linked: 1
- Matterne U, Böhmer MM, Weisshaar E, Jupiter A, Carter B, Apfelbacher CJ. Oral H1 antihistamines as ‘add-on’ therapy to topical treatment for eczema. Cochrane Database Syst Rev 2019;1:CD012167-CD012167.30666626
Cited by
Items 301–369 of 369
Complications oculaires induites par le dupilumab au cours du traitement de la dermatite atopique
Cassagne, M., Galiacy, S. D., Tauber, M., Paul, C. F., Fournié, P., & Simon, M. (2021) · Revue française d'allergologie · doi:10.1016/j.reval.2021.07.002
Research-and-teaching elective in a primary care oriented school.
Pantoja, E., Zambernard, J., Nagy, F., Ream, L., & Rj, M. (1984) · PubMed
Emerging therapies in pediatric atopic dermatitis patients
Bowles, A., Logas, C. M., Glick, B. P., & Rosso, J. Q. D. (2022) · Dermatological Reviews · doi:10.1002/der2.115
Klinische Dermatologie: Die Pipelines sind gefüllt
Frings, V. G., & Goebeler, M. (2021) · Deutsches Ärzteblatt · doi:10.3238/persderma.2021.06.18.01
Morán‐Villaseñor, E., & García‐Romero, M. T. (2022) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815039658122010012
Patent Highlights February–March 2022
Mucke, H. A. (2022) · Pharmaceutical Patent Analyst · doi:10.4155/ppa-2022-0013
Therapies for atopic dermatitis: still moving forward
Kämmerer, S. (2022) · doi:10.55788/25a7d0de
Rôle de l’interleukine 31, une cytokine neuro-immune, dans le prurit et au-delà
Misery, L. (2023) · Annales de Dermatologie et de Vénéréologie - FMC · doi:10.1016/j.fander.2022.12.005
Special Therapeutic Options and Substances in the Treatment of Atopic Eczema
Eyerich, K., & Ring, J. (2023) · Springer eBooks · doi:10.1007/978-3-031-12499-0_7 · Cited by 2
D’Erme, A. M., Bagnoni, G., & Bos, J. D. (2023) · Springer eBooks · doi:10.1007/978-3-031-15130-9_7
A review of biological agents and small molecules in the management of atopic dermatitis
Ramani, A. A., Bose, S., Madke, B., Prakashey, A. R., & Ganjre, S. (2023) · Indian Journal of Skin Allergy · doi:10.25259/ijsa_18_2023
Biologic drugs, a new therapeutic paradigm in moderate-severe atopic dermatitis
Vignoli, C. A., & Borroni, R. G. (2023) · doi:10.37349/eaa.2023.00020
Wu, H.-H., & You, Y. (2023) · International Journal of Dermatology and Venereology · doi:10.1097/jd9.0000000000000364
Anti-IL-31 receptor alpha monoclonal antibody: Nemolizumab
Matsuzaki, H., & Odajima, H. (2023) · Nihon Shoni Arerugi Gakkaishi The Japanese Journal of Pediatric Allergy and Clinical Immunology · doi:10.3388/jspaci.37.497
Biologics in the Management of Sever Atopic Dermatitis
Abadie, M. A., Sharara, Z., & Al Abadie, S. (2023) · International Journal of Clinical & Experimental Dermatology · doi:10.33140/ijced.08.02.05
Skayem, C., & Duong, T. A. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1004103 · Cited by 1
IL-31: A Potential Implication in CAR T Cells Neurotoxicity?
Arbab, A., Moujaess, E., Srikanthan, J., Ammari, S., Vergé, V., Danu, A., Ghez, D., Kodvanzik, L. M., Bigé, N., Stoclin, A., et al. (2023) · Annals of Case Reports · doi:10.29011/2574-7754.101535
Rosso, J. Q. D. (2024) · Clinical Cases in Dermatology · doi:10.1007/978-3-031-52147-8_20
Schreml, S. (2024) · Wiley eBooks · doi:10.1002/9781119709268.rook056
Targeted Therapy for Atopic Dermatitis: A Novel Approach
Chauhan, M., Mazumder, R., Rani, A., Kumar, A., & Chaitanya, M. (2024) · Current Drug Therapy · doi:10.2174/0115748855307501240607045747
ATOPİK DERMATİT TEDAVİSİNDE BİYOLOJİK İLAÇLAR: LİTERATÜR TARAMASI
Çalıcıoğlu, F., Çalıcıoğlu, N., Avcı, A., Ulaş, Y., & Ertaş, R. (2024) · Journal of Anatolian Medical Research · doi:10.55694/jamer.1410278 · Cited by 1
OTSUKA, A. (2024) · The Nishinihon Journal of Dermatology · doi:10.2336/nishinihonhifu.86.361
Gudjonsson, J. E., & Elder, J. T. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-812531-1.00010-5
Sosin, J., Pilarz, A., Stachowiak, J., Zwierzchowska, M., Sojka, A., Salamon, D., & Domagała, W. (2024) · Quality in Sport · doi:10.12775/qs.2024.31.55934
IL-31 suppresses the expression of TARC/CCL17 in TNF-alpha/IFN-gamma-stimulated HaCaT keratinocytesPreprint
Iwamoto, M., Takafuji, T., Yamada, Y., & Fujita, T. (2025) · Research Square · doi:10.21203/rs.3.rs-6260398/v1
Diagnosis and treatment of atopic dermatitis
Kołakowska, K., Kurzyna, P. F., Czubek, M., Lis, I., & Piech, G. M. (2024) · Biuletyn Głównej Biblioteki Lekarskiej · doi:10.2478/bgbl-2024-0033
Treatment Safety in Pediatric Atopic Dermatitis
Ecalnir, M. (2025) · Dominican Scholar (Dominican University of California) · doi:10.33015/dominican.edu/2025.nurs.st.47
A study of 10 cases of highly pruritic atopic dermatitis treated with nemolizumab
Okusa, Y., & Fukuda, T. (2025) · 日本臨床皮膚科医会雑誌 · doi:10.3812/jocd.42.574
Prurito: cómo abordarlo y tratarlo
Triviño, F. N. (2025) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/j.fmc.2024.12.005
Vieira, A. C. P., Akabane, M. A. C. C., Caletti, G. C. G., Heffel, K. K., & Silva, A. T. O. E. (2025) · Anais Brasileiros de Dermatologia (Versão em Português) · doi:10.1016/j.abdp.2025.501210
Biologics in the Treatment of Atopic Dermatitis
Sharara, Z. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1013012 · Cited by 1
Hua, C., Liang, Q., Chen, S., Zhu, J., Tang, Y., Chen, X., Song, Y., van der Veen, S., & Cheng, H. (2023) · Figshare · doi:10.6084/m9.figshare.23258832
Hua, C., Liang, Q., Chen, S., Zhu, J., Tang, Y., Chen, X., Song, Y., van der Veen, S., & Cheng, H. (2023) · Figshare · doi:10.6084/m9.figshare.23258829
Hua, C., Liang, Q., Chen, S., Zhu, J., Tang, Y., Chen, X., Song, Y., van der Veen, S., & Cheng, H. (2023) · Figshare · doi:10.6084/m9.figshare.23258826
Hua, C., Liang, Q., Chen, S., Zhu, J., Tang, Y., Chen, X., Song, Y., van der Veen, S., & Cheng, H. (2023) · Figshare · doi:10.6084/m9.figshare.23258823
Hua, C., Liang, Q., Chen, S., Zhu, J., Tang, Y., Chen, X., Song, Y., van der Veen, S., & Cheng, H. (2023) · Figshare · doi:10.6084/m9.figshare.23258835
New molecules in management of atopic dermatitis
Leong, K. F., Albela, H., Lee, W. Q., & Latiff, A. H. A. (2025) · Indian Journal of Skin Allergy · doi:10.25259/ijsa_6_2025 · Cited by 1
ATOPIC DERMATITIS: ADVANCES IN PATHOPHYSIOLOGY AND NEW IMMUNOLOGICAL THERAPIES.
Núñez, S. V. R., Sánchez, E. J. O., Yaguana, G. A. L., Henriquez, C. P. H., Sánchez, R. D. C., Galarza, N. X. C., Cueva, E. E. E., Peña, M. L. C., Torres, D. E. P., Guarnizo-Orellana, L. A., et al. (2025) · International Journal of Health Science · doi:10.22533/at.ed.1595302518097
Biological Treatments in Atopic Dermatitis: Current Treatments and Future Directions
Mergen, M. A., Çetinarslan, T., & Ermertcan, A. T. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1009403
Chapter III: differential diagnosis, clinical evaluation, biomarker
Natsume, O., Horino, S., Miura, K., Morio, T., & Katoh, N. (2025) · Nihon Shoni Arerugi Gakkaishi The Japanese Journal of Pediatric Allergy and Clinical Immunology · doi:10.3388/jspaci.39.436
Nemolizumab as an Alternative Therapeutic Option for Indolent Systemic Mastocytosis
Minbaeva, S., & Tyring, S. K. (2026) · Cureus · doi:10.7759/cureus.101086
Eghleilib, M., Eghlileb, M., & Eghlileb, A. M. (2026) · Cureus · doi:10.7759/cureus.103223 · Cited by 2
Nakajima, S., Iizuka, H., TAIRA, K., Tanaka, K., Hashimoto, K., Kaneda, N., Iwasaki, K., Takafuji, T., Yamada, Y., & Kabashima, K. (2026) · JID Innovations · doi:10.1016/j.xjidi.2026.100457
Self-citationSun, X.-G., Yang, B., Yang, X., Li, F., & Hao, L.-J. (2026) · South African Journal of Botany · doi:10.1016/j.sajb.2026.02.016
Jędrzejczak, Z. K., Babiński, P. J., Wiśniewska, M., Horabik, A. J., Dmochowska, M., Hertmanowska, J., Piotrowska, M., Chmura, K., Piekarska, A. A., & Kryger, G. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.4772
Update on Biologic Therapy for Atopic Dermatitis
Giannetti, A., Ciacera, F. L., Buono, E. V., Giannì, G., & Caffarelli, C. (2026) · Rivista di immunologia ed allergologia pediatrica. · doi:10.53151/2531-3916/2025-1673 · Cited by 3
The Role of ILC2s in Tissue Injury and Repair
Jun, S., Ruifeng, W., & Qi, C. (2026) · Immune discovery. · doi:10.70322/immune.2026.10001
藤田, 雄. (2024) · Institutional Repositories DataBase (IRDB)
Role of mast cell-nociceptor interactions in the development of skin inflammation
Serhan, N. (2021) · theses.fr (ABES) · doi:10.70675/b0572080z1474z40a2zb12dzf7b795739608 · Cited by 1
Lefèvre‐Utile, A. (2021) · theses.fr (ABES) · doi:10.70675/e862df74z545az4e0bza70az48ee9411c538
Ebi, N., Kogame, T., Ishida‐Yamamoto, A., Akasaka, E., & Kabashima, K. (2026) · Clinical and Experimental Dermatology · doi:10.1093/ced/llag186
Self-citationKawashima, M., Maeda, T., Iwasaki, K., Takizawa, M., Kaneda, N., & Kabashima, K. (2026) · Dermatology and Therapy · doi:10.1007/s13555-026-01768-0
Self-citationGao, X., Cai, R., Lu, J., Duan, Z., Xu, Q., Zhang, X., Shen, F., Zhang, R., Li, B., & Wang, R. L. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1845534 · Cited by 1
Monoclonal Antibodies in Pediatric Atopic Dermatitis; Efficacy and Safety
Masoumi, N., Monadi, T., Aminzade, Z., Soltani, A., Noqani, H., & Enderami, S. E. (2026) · Current Therapeutic Research · doi:10.1016/j.curtheres.2026.100833
Adam, D. N., Dhadwal, G., Grewal, P. S., Ringuet, J., Turchin, I., & Beecker, J. R. (2026) · Dermatologic Therapy · doi:10.1155/dth/6874662
Review on the Application of Biologic Factors in Atopic Dermatitis and Chronic Spontaneous Urticaria
Salavoura, A. (2026) · Dermatology Research and Practice · doi:10.1155/drp/5283760
Seiter, D., & Babani, K. (2026) · JAAD Case Reports · doi:10.1016/j.jdcr.2026.06.049
Soenoe, M. S., & Hadi, S. (2026) · Archives of Dermatological Research · doi:10.1007/s00403-026-04760-y
Nonpruritic Eczematous Flares During Nemolizumab Therapy: A Case Series
Pabian, L., Karpoff, K., & Lebwohl, M. (2026) · International Journal of Dermatology · doi:10.1111/ijd.70596
A 48-week real-world effectiveness of nemolizumab for pediatric patients with atopic dermatitis
Hagino, T., Takahashi, Y., Saeki, H., Fujimoto, E., & Kanda, N. (2026) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2026.07.118
Autosomal recessive OSMRβ deficiency: Connecting OSM and/or IL-31 with atopy
Puel, A., Casanova, J., & Béziat, V. (2026) · Journal of Human Immunity · doi:10.70962/jhi.20260115
A Case of Bullous Pemphigoid Following Nemolizumab Treatment in a Patient with Atopic Dermatitis
Takuya, M. A. K. I., KIKUCHI, Y., Kato, S., Tago, M., HOTTA, M., & MITSUMA, T. (2026) · The Nishinihon Journal of Dermatology · doi:10.2336/nishinihonhifu.88.333
Feng, Y., Qian, G., Wei, Z., & Dong, X. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.113472
Atopic Dermatitis and Sleep Disorders
Bai, G., Shao, X., Ou, Y., Chen, J., Tan, Z., Chen, A., & Zhang, J. (2026) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2026.18.5.751 · Cited by 1
IL-31 targets the hair follicle bulge across species and delays plucking-induced anagen in mice
Katsuo, K., Nakamizo, S., Egawa, G., Kitoh, A., Nakajima, S., Okada, T., & Kabashima, K. (2026) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2026.10.005
Self-citationZhang, L., Meng, Z., Bo, H., Tian, Y., 牟伟才, Ping, X., Dong, J., & Li, Y. L. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.11.758381
Armstrong, A. W., Kim, H., Pink, A., Gorelick, J., Rossi, M., Trzeciak, M., Deleuran, M. S., Nakajima, S., & Prajapati, V. H. (2026) · Dermatology and Therapy · doi:10.1007/s13555-026-01942-4
Routine Clinical Nemolizumab Use Before or After Cutaneous T-Cell Lymphoma Diagnosis
Nayudu, K., Vasavda, C., Buckhoree, F., Kupper, T. S., Shahriari, N., Chen, S., Meltzer, R., Stephen, S., & Larocca, C. A. (2026) · JAMA Dermatology · doi:10.1001/jamadermatol.2026.4305
Metadata
- Authors
- Kabashima, K., Matsumura, T., Komazaki, H., & Kawashima, M.
- Affiliations
- Kyoto University (JP)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-07-09
- Volume
- 383
- Issue
- 2
- Pages
- 141-150
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3040869725
- Cited by
- 361
- References
- 39
- Citations by year
- 2026: 37 · 2025: 68 · 2024: 57 · 2023: 67 · 2022: 51 · 2021: 73 · 2020: 7
- FWCI
- 36.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Maruho co., Ltd.
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- atopic dermatitis, pruritus, nemolizumab, monoclonal antibodies, topical corticosteroids, topical calcineurin inhibitors, Eczema Area and Severity Index, Dermatology Life Quality Index, insomnia, Japanese patients, treatment efficacy and safety, visual analogue scale
- MeSH terms
- Administration, Topical, Adolescent, Adult, Aged, Aged, 80 and over, Dermatitis, Atopic, Double-Blind Method, Drug Therapy, Combination, Female, Glucocorticoids, Histamine Antagonists, Humans, Injections, Subcutaneous, Male, Middle Aged, Pruritus, Young Adult, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized, Visual Analog Scale, Calcineurin Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.